Related Experiment Video
Updated: Apr 30, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Left atrial appendage devices for stroke prevention in atrial fibrillation
Sarah K Hussain1, Rohit Malhotra, John P DiMarco
1The University of Virginia, Charlottesville, VA, USA, skh6c@virginia.edu.
Insights
Atrial fibrillation (AF) stroke risk can be reduced by left atrial appendage (LAA) occlusion devices. These devices offer an alternative to oral anticoagulants for patients with contraindications.
Area of Science:
- Cardiology
- Medical Devices
- Thrombosis
Background:
- Atrial fibrillation (AF) is a common arrhythmia requiring stroke prevention.
- Oral anticoagulants are effective but have limitations, driving the need for alternatives.
- The left atrial appendage (LAA) is a primary source of thrombi in non-valvular AF.
Purpose of the Study:
- To review current left atrial appendage (LAA) occlusion devices.
- To examine the evidence supporting LAA occlusion for stroke prevention in AF.
- To assess the potential of LAA occlusion as an alternative to anticoagulation.
Main Methods:
- Review of existing literature on LAA occlusion devices.
- Analysis of clinical evidence regarding safety and efficacy.
- Exploration of device-based stroke prevention strategies in AF.
Main Results:
- LAA occlusion aims to reduce systemic thromboembolic events.
- Several LAA occlusion devices are currently available.
- Evidence from randomized trials is still needed to fully establish safety and efficacy.
Conclusions:
- LAA occlusion presents a promising alternative for stroke risk reduction in AF patients.
- It may be particularly beneficial for patients with contraindications to anticoagulant therapy.
- Further randomized trial data are essential for widespread adoption and understanding of LAA occlusion devices.
Abstract:
Atrial fibrillation (AF) is the most commonly encountered clinical arrhythmia, and stroke prevention remains an integral part of management of AF. Long-term therapy with oral anticoagulants, though effective, has many limitations, and these limitations have encouraged the search for device-based alternatives. In patients with non-valvular AF, approximately 90% of thrombi are thought to arise from the left atrial appendage (LAA). The LAA can be obliterated surgically or percutaneously, and this should reduce the incidence of systemic thromboembolic events in AF, ideally without the need for further anticoagulation. We explore the currently available LAA occlusion devices and the evidence behind these devices. Although additional evidence from randomized trials is required to fully characterize the safety and efficacy of all of these devices, LAA occlusion has the potential to offer an attractive alternative for those at high stroke risk but are under-protected because of contraindications to anticoagulant therapy.
